Who We Are
Curae Pharma360 has significant experience in developing and commercializing the medicines people need.
Chief Executive Officer
Autumn Ehnow is the Chief Executive Officer of Curae Pharma360 and also serves as Executive Vice President, Policy & Strategic Market Access at Medicines360, the nonprofit parent company of Curae. Autumn’s two decades as a pharmaceutical and nonprofit leader, and personal experiences when needed medications were out of reach, have informed her drive and dedication to addressing the gap in equitable access to crucial medicines. With a strong track record of structuring and managing business partnerships in the U.S. and across the globe, and her role establishing the commercial operations at Curae, Autumn sets the strategy and guides plans to scale the organization. Autumn has spent 10 years at for-profit pharmaceutical companies and over 15 years in non-profit pharmaceutical entities with a history of leading successful partnerships with both governmental agencies and private pharmaceutical companies to develop new medicines for both small and large molecule products. At the Institute for OneWorld Health, she was integral in forming and managing the Bill and Melinda Gates Foundation grant and the multi-company partnership that brought semi-synthetic Artemisinin to market. As part of the original founding team of Medicines360, she helped define and lead the program strategy and implementation that brought the hormonal IUD to market in the USA, breaking down barriers to access in the process. She is a frequent presenter on health equity topics, and holds a BS in Molecular and Cellular Biology.
Brad Luke, MBA
Chief Financial Officer
Brad Luke is a senior financial executive with over thirty years of experience in finance and accounting for the pharmaceutical, healthcare, technology, and non-profit industries. Mr. Luke heads finance, accounting, human resources, and IT functions for Curae Pharma360. He previously served as the CFO at Archimedes, Inc. — a for-profit healthcare analytics company owned by Kaiser Permanente and partially funded by the Robert Wood Johnson Foundation — as well as VP/Controller at Arcadian Health Plan — a start-up HMO in Oakland, CA. Mr. Luke received his MBA and BA in Finance from California State University, Fullerton.
Mark Busch, PhD
Senior Vice President, Quality and Product Safety
Mark Busch brings over 25 years of experience in quality assurance/quality control, analytical, and regulatory support of GxP operations. His extensive experience includes senior-level quality positions, having served as Vice President of Quality Assurance at NeurogesX, and holding positions at Geron, VaxGen, InterMune, and Scios. As a senior quality executive, Dr. Busch has demonstrated leadership and expertise in developing and implementing quality systems to ensure GxP and regulatory compliance, supporting a broad range of pharmaceutical products throughout the product lifecycle. In addition, Dr. Busch has published several peer reviewed articles and developed his own successful pharmaceutical consulting business. Dr. Busch holds a PhD in Biological Chemistry from Indiana University and performed post-doctoral research at Carnegie Mellon University.
Head of Supply Chain
Sooraj Nair has over a decade of experience in leading end-to-end supply chain and product lifecycle management across various industries. He brings a unique set of skills, with his diverse background in business processes and a powerful grip on leading-edge technologies. He has led multiple cost-saving and process-enabling projects, all while improving customer service with Pepperidge Farm Inc. (part of Campbell Soup), DuPont, Fitbit & Gilead Sciences. Nair is alumni of Syracuse University and holds supply chain certificates from MIT and ASCM (formerly known as APICS).
Emily Morris, MS, RAC-US
Head of Regulatory
Emily Morris oversees the Regulatory Department at Curae Pharma360. Her experience includes regulated drug, device, and drug-device products in the U.S., Africa, and Southeast Asia. She informs and executes regulatory strategy for product development and post-marketing, including clinical trial operations, product registration, and product lifecycle management (manufacturing, labeling, and pharmacovigilance). Morris received a Bachelor of Arts degree in Political Science and Government from Purdue University and a Master of Science degree in Strategic Regulatory Affairs from Northeastern University. She has maintained her Regulatory Affairs Certification from the Regulatory Affairs Professional Society since 2015.